AstraZeneca (AZN) call put ratio 1 call to 3.6 puts into shares selling off 15% on failed drug trial

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 6/23/2026

1. SPCX
2. NVDA
3. ACN
4. MU
5. GOOGL
6. APGE
7. ABBV
8. USO
9. MSFT
10. IBM

Go back to AstraZeneca (AZN) call put ratio 1 call to 3.6 puts into shares selling off 15% on failed drug trial

AstraZeneca (AZN) Posts Q2 EPS of $0.38; Reiterates Outlook

July 27, 2017 6:56 AM EDT

AstraZeneca (NYSE: AZN) reported Q2 EPS of $0.38 and core EPS of $0.87 versus analyst estimate of $0.42. Revenue for the quarter came in at $5.05 billion versus the consensus estimate of $5.07 billion.

The residual effects of the Crestor and Seroquel XR loss of exclusivity in the US... More